Mode
Text Size
Log in / Sign up
N/A Completed N=21 Treatment

Early CPAP And Large Volume Minimally Invasive Surfactant (ECALMIST) in Preterm Infants With RDS

Source: ClinicalTrials.gov NCT01553292 ↗
Enrolled (actual)
21
Serious AEs
14.3%
Results posted
Jul 2013
Primary outcomePrimary: Incidence of Early Ventilation Hours — 4 Number of participants

Summary

Modification of Minimally Invasive Surfactant Therapy (MIST) to a new technique called ECALMIST (Early CPAP And Large volume Minimal Invasive Surfactant). This modification is needed to adapt the use of large volume surfactant of 4-5 ml/kg. The ECALMIST will be used to deliver the large volume Surfactant that been used in Canada called BLES (about 5 ml for each 100 mg) to the preterm infants bellow 35 weeks gestation suffer from respiratory distress syndrome (RDS) in 1st 24 hours of life while maintained on CPAP.

Outcome Measures

OutcomeResultp-value
PRIMARY
Incidence of Early Ventilation Hours
4
SECONDARY
Incidence of Bradycardia During Procedure
3
SECONDARY
Saturation During the Procedure
0.87
SECONDARY
Failure to Catheterized the Trachea by the Vascular Catheter
1
SECONDARY
Index Before the Procedure
2.61
SECONDARY
CPAP Pressure After the Procedure
5.8
SECONDARY
Oxygen Requirement Before the Procedure
0.308
SECONDARY
Oxygen Saturation After the Procedure
0.94
SECONDARY
Index After the Procedure
1.27
SECONDARY
CPAP Pressure Before the Proceudre
7.1
SECONDARY
Oxygen Saturation Before the Procedure
0.87
SECONDARY
Oxygen Requirements After the Procedure
0.257
SECONDARY
Needs for Intubation During the Procedure
3

Eligibility Criteria

Inclusion Criteria

-preterm infants less than 35 weeks gestation in 1st day of life with RDS and spontaneously breathing on CPAP and need surfactant administration.

Exclusion Criteria

  • Infants needs of mechanical ventilation
  • Congenital anomaly
  • Respiratory distress due to non RDS related causes.
  • no parental consent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01553292). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search